Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

News · June 11, 2019

ASCO 2019: SOPHIA Trial Shows Promise for Margetuximab in HER2-Positive Breast Cancer

This is the first trial to use CD16A genotype as a predictor of response

PracticeUpdate Editorial Team

 

Additional Info

Disclosure statements are available on the authors' profiles:

Further Reading